Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.57 |
| ▸ | PDE4A | P27815 | 9/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15580910 | 1.00 | PDE4B (0.57) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15580962 | 0.92 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15580934 | 0.92 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15580932 | 0.88 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15580926 | 0.86 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL753579 | 0.86 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15869339 | 0.86 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15580915 | 0.86 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15869362 | 0.86 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL302947 | 0.86 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642836-B2 | Isotopologues of isoindole derivatives | CELGENE CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9434689-B2 | Processes for the preparation of isoindole compounds and isotopologues thereof | CELGENE CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150258063-A1 | ISOTOPOLOGUES OF ISOINDOLE DERIVATIVES | AMGEN INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150183739-A1 | PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF | AMGEN INC. | 2015-07-02 | — | — | US | disclosed |
| US-9045417-B2 | Isotopologues of isoindole derivatives | CELGENE CORPORATION (US) | 2015-06-02 | — | — | US | disclosed |
| US-8981117-B2 | Processes for the preparation of isoindole compounds and isotopologues thereof | CELGENE CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140194485-A1 | ISOTOPOLOGUES OF ISOINDOLE DERIVATIVES | CELGENE CORPORATION (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140081032-A1 | PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF | CELGENE CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183739-A1 | PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF | HPD, DHPS, IDH2 | PDE4B 1021/4885PDE4A 1248/4885PDE4C 1388/4885 |
| US-20140081032-A1 | PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF | HPD, DHPS, IDH2 | PDE4B 1021/4885PDE4A 1248/4885PDE4C 1388/4885 |
| US-20140194485-A1 | ISOTOPOLOGUES OF ISOINDOLE DERIVATIVES | IDO1, CYP11B2, IDO2 | PDE4B 1306/4885PDE4A 1635/4885PDE4C 1991/4885 |
| US-20150258063-A1 | ISOTOPOLOGUES OF ISOINDOLE DERIVATIVES | IDO1, CYP11B2, IDO2 | PDE4B 1306/4885PDE4A 1635/4885PDE4C 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.